Alzheimer’s disease research has taken another hit with the termination of a Phase III study assessing the effect of diabetes drug pioglitazone on mild cognitive impairment (MCI) in patients with the condition. More: Takeda/Zinfadel terminate late-stage Alzheimer’s study Source: News
read moreLondon, UK-based Rexgenero has reached a major milestone in treating the first patient in a late-stage trial with its lead product, cell therapy REX-001. More: Rexgenero treats first patients in CLI trial Source: News
read moreSore throats should be treated with painkillers and not antibiotics, according to new guidelines produced by the National Institute for Health and Care Excellence and Public Health England. More: NICE/PHE against blanket use of antibiotics for sore throats Source: News
read moreJohnson & Johnson has plenty of money coming in from overseas, thanks to U.S. tax reform. But it won’t be spending it on Pfizer’s consumer health unit. More: Johnson & Johnson drops out of the race for Pfizer consumer unit,
read moreBiogen CEO Michel Vounatsos doesn’t “see a frenzy” of M&A coming to pharma because of an influx of overseas cash. But what activity he does predict? He expects to be part of it. More: Biogen's in the hunt for late-stage
read moreDespite its struggles in 2017, Celgene turned in 16% sales growth for the year, buoyed by key drugs Revlimid, Pomalyst and Otezla. And some recent M&A could keep the growth coming. More: On heels of Juno deal, Celgene reports volume-driven
read more© 1994 - 2026 B.M. Pharmaceuticals